VTRS · Viatris Inc · Investor Relations
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Upcoming events
| Date | Event | Type |
|---|---|---|
| 2026-11-17 10:00 UTC | UBS Global Biopharma Conference | Conference |
| 2026-11-18 09:00 UTC | Jefferies Global Healthcare Conference in London | Conference |
| 2026-12-01 13:45 UTC | Evercore 9th Annual Healthcare Conference | Conference |
Recent news
| Date | Headline |
|---|---|
| 2026-11-11 | Viatris to Participate in Upcoming Investor Conferences |
| 2026-11-05 | Viatris Reports Third-Quarter 2026 Financial Results |
| 2026-11-04 | Viatris Announces Quarterly Dividend |
| 2026-10-30 |
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
PITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. (" Viatris ") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to purchase all of the issued and outstanding shares of |
| 2026-10-30 | Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc. |
| 2026-10-16 |
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
PITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration ( FDA) has approved RYZUMVI ® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. |
| 2026-10-16 | Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia |
| 2026-10-08 |
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global R&D |
| 2026-10-08 | Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies |
| 2026-10-05 |
Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
PITTSBURGH, Oct. 5, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report third-quarter 2026 financial results on Thursday, November 5, 2026. Company executives will host a conference call and live webcast at 8:30 a.m. |
| 2026-10-05 | Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026 |
| 2026-09-29 |
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
PITTSBURGH, Sept. 29, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it was named to Forbes' World's Best Employers list for the sixth consecutive year. The ranking is presented by Forbes and Statista, the world-leading statistics portal and |
| 2026-09-29 | Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year |
| 2026-09-16 |
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
Approval Addresses High Unmet Medical Need and Further Advances Viatris' Innovative Portfolio in Japan PITTSBURGH, Sept. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for |
| 2026-08-06 |
Viatris Reports Second-Quarter 2026 Financial Results
Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025 Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second |
| 2026-08-04 |
Viatris Announces Quarterly Dividend
PITTSBURGH, Aug. 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on August 3, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on September 16, 2026, |
| 2026-07-29 |
Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
New Patch Will Provide Low-Dose Estrogen Combined Hormonal Contraceptive Option Approval Marks an Important Milestone in Viatris' Efforts to Advance Women's Health PITTSBURGH, July 29, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. |
| 2026-07-01 |
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
PITTSBURGH, July 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report second-quarter 2026 financial results on Thursday, August 6, 2026. Company executives will host a conference call and live webcast at 8:30 a.m. |
| 2026-06-29 |
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy
VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies Japanese New Drug Application Submission Targeted by End of 2026 PITTSBURGH and TOKYO, June 29, 2026 |
| 2026-05-18 |
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
FDA PDUFA Goal Date Set for Dec. 27, 2026 PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting |
| 2026-05-07 |
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference
PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8 a.m. PT / 11 a.m. ET. |
| 2026-05-07 |
Viatris Reports First-Quarter 2026 Financial Results
Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million Total Revenues Were Up 3% Operationally Compared to First Quarter 2025 Adjusted EBITDA was $1.0 Billion Up 10% Operationally Compared to First |
Past events
Source: https://investor.viatris.com/